The protective effect and mechanism of catalpol on high glucose-induced podocyte injury

被引:51
作者
Chen, Yan [1 ]
Liu, Qingpu [1 ]
Shan, Zengfu [1 ]
Zhao, Yingying [1 ]
Li, Meng [1 ]
Wang, Baiyan [2 ]
Zheng, Xiaoke [1 ,3 ]
Feng, Weisheng [1 ,3 ]
机构
[1] Henan Univ Chinese Med, Coll Pharm, Zhengzhou 450046, Henan, Peoples R China
[2] Henan Univ Chinese Med, Coll Basic Med, Zhengzhou 450046, Henan, Peoples R China
[3] Collaborat Innovat Ctr Resp Dis Diag & Treatment, Zhengzhou 450046, Henan, Peoples R China
来源
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2019年 / 19卷 / 01期
关键词
Rehmannia glutinosa; Catalpol; Podocyte injury; Diabetic nephropathy; Mechanism; OXIDATIVE STRESS; DIABETIC-NEPHROPATHY; INFLAMMATORY RESPONSES; CELL DYSFUNCTION; KIDNEY-DISEASE; APOPTOSIS; AUTOPHAGY; INHIBITION; EXPRESSION; PATHWAY;
D O I
10.1186/s12906-019-2656-8
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background Catalpol, a natural iridoid glycoside in Rehmannia glutinosa, can alleviate proteinuria associated with diabetic nephropathy (DN), however, whether catalpol has a protective effect against podocyte injury in DN remains unclear. Methods In this study, we used a high glucose (HG)-induced podocyte injury model to evaluate the protective effect and mechanism of catalpol against HG-induced podocyte injury. Cell viability was determined by the 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The levels of lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA) were measured by commercial assay kits. Cell apoptosis and reactive oxygen species (ROS) were determined by using flow cytometry. Tumour necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) levels were determined by enzyme-linked immunosorbent assay (ELISA). The protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl2-associated x (Bax), cleaved caspase-3, nicotinamide adenine dinucleotide phosphate oxidase enzyme 4 (NOX4), toll-like receptor 4 (TLR4), myeloid differentiation primary response gene 88 (MyD88), p38 mitogen-activated protein kinase (p38 MAPK), phosphorylated p38 MAPK (p-p38 MAPK), nuclear factor kappa B inhibitor alpha (I kappa B alpha) and phosphorylated I kappa B alpha (p-I kappa B alpha) were measured by western blotting. In addition, Bcl-2, Bax, caspase-3 and nuclear factor kappa B (NF-kappa B) levels were determined by immunofluorescence staining. Results Catalpol significantly increased cell viability and decreased LDH release in HG-induced podocyte injury. Catalpol significantly decreased ROS generation, apoptosis, level of MDA, levels of inflammatory cytokine TNF-alpha, IL-1 beta, and IL-6 and increased SOD activity in HG-induced podocyte injury. Moreover, catalpol significantly decreased expression of cleaved caspase-3, Bax, NOX4, TLR4, MyD88, p-p38 MAPK, p-I kappa B alpha and NF-kappa B nuclear translocation, as well as increased Bcl-2 expression in HG-induced podocyte injury. Conclusion Catalpol can protect against podocyte injury by ameliorating apoptosis and inflammation. These protective effects may be attributed to the inhibition of NOX4, which alleviates ROS generation and suppression of the TLR4/MyD88 and p38 MAPK signaling pathways to prevent NF-kappa B activation. Therefore, catalpol could be a promising drug for the prevention of DN.
引用
收藏
页数:10
相关论文
共 54 条
[1]   The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial (Publication with Expression of Concern. See vol. 127, pg. 155, 2022) [J].
Bahmani, Fereshteh ;
Kia, Mahsa ;
Soleimani, Alireza ;
Mohammadi, Ali Akbar ;
Asemi, Zatollah .
BRITISH JOURNAL OF NUTRITION, 2016, 116 (07) :1222-1228
[2]   Enhanced Expression of Janus Kinase-Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy [J].
Berthier, Celine C. ;
Zhang, Hongyru ;
Schin, MaryLee ;
Henger, Anna ;
Nelson, Robert G. ;
Yee, Berne ;
Boucherot, Anissa ;
Neusser, Matthias A. ;
Cohen, Clemens D. ;
Carter-Su, Christin ;
Argetsinger, Lawrence S. ;
Rastaldi, Maria P. ;
Brosius, Frank C. ;
Kretzler, Matthias .
DIABETES, 2009, 58 (02) :469-477
[3]   Catalpol inhibits LPS plus IFN-γ-induced inflammatory response in astrocytes primary cultures [J].
Bi, Jing ;
Jiang, Bo ;
Zorn, Andrew ;
Zhao, Rong-Guo ;
Liu, Peng ;
An, Li-Jia .
TOXICOLOGY IN VITRO, 2013, 27 (02) :543-550
[4]   Epigallocatechin-3-gallate attenuates lipopolysaccharide-induced mastitis in rats via suppressing MAPK mediated inflammatory responses and oxidative stress [J].
Chen, Jinglou ;
Xu, Jun ;
Li, Jingjing ;
Du, Lifen ;
Chen, Tao ;
Liu, Ping ;
Peng, Sisi ;
Wang, Mingwei ;
Song, Hongping .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 26 (01) :147-152
[5]   Taiwanese Green Propolis Ethanol Extract Delays the Progression of Type 2 Diabetes Mellitus in Rats Treated with Streptozotocin/High-Fat Diet [J].
Chen, Li-Han ;
Chien, Yi-Wen ;
Chang, Mei-Ling ;
Hou, Chia-Chung ;
Chan, Ching-Hung ;
Tang, Hung-Wei ;
Huang, Hui-Yu .
NUTRIENTS, 2018, 10 (04)
[6]   Neuroprotective activities of catalpol against CaMKII-dependent apoptosis induced by LPS in PC12 cells [J].
Chen, Wenna ;
Li, Ximing ;
Jia, Lian-Qun ;
Wang, Jun ;
Zhang, Lin ;
Hou, Diandong ;
Wang, Junyan ;
Ren, Lu .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 169 (05) :1140-1152
[7]   RETRACTED: Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression (Retracted Article) [J].
Chen, Xiaoping ;
Zhao, Lei ;
Xing, Yanwei ;
Lin, Bo .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 108 :7-14
[8]   Catalpol suppresses advanced glycation end-products-induced inflammatory responses through inhibition of reactive oxygen species in human monocytic THP-1 cells [J].
Choi, Hee-Jung ;
Jang, Hye-Jin ;
Chung, Tae-Wook ;
Jeong, Seung-Il ;
Cha, Jaeho ;
Choi, Jun-Young ;
Han, Chang Woo ;
Jang, Yong-Suk ;
Joo, Myungsoo ;
Jeong, Han-Sol ;
Ha, Ki-Tae .
FITOTERAPIA, 2013, 86 :19-28
[9]   Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts) [J].
D'Agati, V. D. .
KIDNEY INTERNATIONAL, 2008, 73 (04) :399-406
[10]  
Deng Yuanjun, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030106